<<  1  2  3  4  5  6  7  8  >>
			continued from cover      This multifaceted approach will result in support for ISB of about $100 million during the next five years.      The scientific projects are the foundation of the partnership. They address several critical objectives through study in two areas – genetic variation in complex systems and the systems biology of disease processes. First, we aim to complete personalized genome sequencing on a large number of individuals within families and to develop novel methods for finding and understanding how genetic variation affects human disease by including all available knowledge of the systems behavior of key molecular processes. Second, we will target new computational methodologies that can integrate data from proteomics, RNA analysis and single-cell analysis to help elucidate the workings of biological networks, distinguishing between health and disease. We will use integrated data to look for diagnostic "fingerprints" in blood-borne molecules that carry information about function in specific organs and that can provide useful information about organ-specific disease processes.      We intend eventually to join these objectives to better understand genetic and environmental influences on the function of complex biological systems and apply this understanding to healthcare. This will truly be a revolution: first scientific, then medical.      Our Luxembourg partners and ISB		have embraced a rare opportunity. The partnership funds substantial cutting edge research at ISB and facilitates development of a European center of excellence in systems biology research. It enables more ambitious research at ISB that can lead to fruitful collaborations worldwide and new external funding opportunities. Our work in creating CSBL and helping it mature into a world-class European institution offers ISB an anchor for a long-term partnership in Europe.      We are now beginning this program, and it is an exciting time. For those of us who already believe in ISB and its mission, we can now more than ever support and illustrate the strength and reach of our scientific ambitions. To those of you who are visionary, similarly ambitious and impatient, but who may not know us well, we invite you to join us in trying to shape the future of healthcare. David Galas, PhD Senior Vice President for Strategic Partnerships Institute for Systems Biology
	PAGE 2				<<  1  2  3  4  5  6  7  8  >>
	© 2009 Institute for Systems Biology. All rights reserved.